Cetuximab-Induced Anaphylaxis and IgE Specific for Galactose-α-1,3-Galactose
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Cetuximab, a chimeric mouse-human IgG1 monoclonal antibody against the epidermal growth factor receptor, is approved for use in colorectal cancer and squamous-cell carcinoma of the head and neck. A high prevalence of hypersensitivity reactions to cetuximab has been reported in some areas of the United States. METHODS: We analyzed serum samples from four groups of subjects for IgE antibodies against cetuximab: pretreatment samples from 76 case subjects who had been treated with cetuximab at multiple centers, predominantly in Tennessee, Arkansas, and North Carolina; samples from 72 control subjects in Tennessee; samples from 49 control subjects with cancer in northern California; and samples from 341 female control subjects in Boston. RESULTS: Among 76 cetuximab-treated subjects, 25 had a hypersensitivity reaction to the drug. IgE antibodies against cetuximab were found in pretreatment samples from 17 of these subjects; only 1 of 51 subjects who did not have a hypersensitivity reaction had such antibodies (P<0.001). IgE antibodies against cetuximab were found in 15 of 72 samples (20.8%) from control subjects in Tennessee, in 3 of 49 samples (6.1%) from northern California, and in 2 of 341 samples (0.6%) from Boston. The IgE antibodies were shown to be specific for an oligosaccharide, galactose-alpha-1,3-galactose, which is present on the Fab portion of the cetuximab heavy chain. CONCLUSIONS: In most subjects who had a hypersensitivity reaction to cetuximab, IgE antibodies against cetuximab were present in serum before therapy. The antibodies were specific for galactose-alpha-1,3-galactose.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Humans also lack the ability to produce the Galα1–3Galβ1–4GlcNAc–R epitope, which is common in murine cells, and this has been shown to induce anaphylaxis [8,33].”
From Glycoengineering Chinese hamster ovary cells: a short history (2021) · cites this paper as [33]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Murine cells can also produce α-gal and Neu5Gc at considerably higher levels than hamster cells, increasing the risks of immunogenicity (Tangvoranuntakul et al., 2003;Chung et al., 2008;Macher and Galili, 2008;Padler-Karavani et al., 2008;Ghaderi et al., 2012).”
From Therapeutic glycoprotein production in mammalian cells (2017) · cites this paper as Chung et al., 2008
Experimental — accuracy not yet measuredIn the citing paper
“However, anti-α-Gal IgE antibodies can cause allergic reactions, such as anaphylaxis, against cetuximab, a therapeutic monoclonal antibody targeting epidermal growth factor receptor (EGFR)”
From ABO blood group antigens and differential glycan expression: Perspective on the evolution of common human enzyme deficiencies (2023) · cites this paper as Chung et al., 2008
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck
Bonner, J. A., Harari, P. M., Giralt, J., Azarnia, N., Shin, D. M., Cohen, R. B., Jones, C. U., Sur, R., Raben, D., Jassem, J., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa053422 · Cited by 5,115
Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033025 · Cited by 5,035
Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis
Edwards, J. C. W., Szczepański, L., Szechiński, J., Filipowicz-Sosnowska, A., Emery, P., Close, D. R., Stevens, R. M., & Shaw, T. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032534 · Cited by 2,623
Saltz, L. B., Meropol, N. J., Loehrer, P. J., Needle, M. N., Kopit, J., & Mayer, R. J. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.10.182 · Cited by 1,694
Chung, K. Y., Shia, J., Kemeny, N. E., Shah, M., Schwartz, G. K., Tse, A., Hamilton, A., Pan, D., Schrag, D., Schwartz, L., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.08.037 · Cited by 1,081
(1945) · Harvard University Press eBooks · doi:10.4159/harvard.9780674184220 · Cited by 1,078
The diagnosis and management of anaphylaxis: An updated practice parameter
LIEBERMAN, P., KEMP, S., OPPENHEIMER, J., LANG, D., BERNSTEIN, I., NICKLAS, R., ANDERSON, J., BERNSTEIN, D., BERNSTEIN, J., & FINK, J. (2005) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2005.01.010 · Cited by 667
Symposium on the Definition and Management of Anaphylaxis: Summary report
Sampson, H. A., Muñoz-Furlong, A., Bock, S. A., Schmitt, C., Bass, R., Chowdhury, B. A., Decker, W. W., Furlong, T. J., Galli, S. J., Golden, D. B., et al. (2005) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2005.01.009 · Cited by 641
The incidence and management of infusion reactions to infliximab: a large center experience
Cheifetz, A. (2003) · The American Journal of Gastroenterology · doi:10.1016/s0002-9270(03)00231-4 · Cited by 491
The anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation
Holgate, S., Casale, T., Wenzel, S., Bousquet, J., Deniz, Y., & Reisner, C. (2005) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2004.11.053 · Cited by 466
Research works printed but not linked: 1
- Carolina; association with atopic history. J Clin Oncol 2007;25:3644-8.
Cited by
Items 101–200 of 1,002
Chinese hamster ovary cells can produce galactose-α-1,3-galactose antigens on proteins
Bosques, C. J., Collins, B. E., Meador, J. W., Sarvaiya, H., Murphy, J. L., DelloRusso, G., Bulik, D. A., Hsu, I.-H., Washburn, N., Sipsey, S. F., et al. (2010) · Nature Biotechnology · doi:10.1038/nbt1110-1153 · Cited by 159
Glycosylation: impact, control and improvement during therapeutic protein production
Costa, A. R., Rodrigues, M. E., Henriques, M., Oliveira, R., & Azeredo, J. (2014) · Critical Reviews in Biotechnology · doi:10.3109/07388551.2013.793649 · Cited by 155
Anaphylaxis syndromes related to a new mammalian cross-reactive carbohydrate determinant
Commins, S. P., & Platts-Mills, T. A. E. (2009) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2009.08.026 · Cited by 155
Self-citationAnaphylaxis in the 21st century: phenotypes, endotypes, and biomarkers
Jimenez-Rodriguez, T., Garcia-Neuer, M., Alenazy, L. A., & Castells, M. (2018) · Journal of Asthma and Allergy · doi:10.2147/jaa.s159411 · Cited by 148
Reducing Immunogenicity by Design: Approaches to Minimize Immunogenicity of Monoclonal Antibodies
Harris, C. T., & Cohen, S. (2024) · BioDrugs · doi:10.1007/s40259-023-00641-2 · Cited by 162
Adverse Events Associated with Anti-EGFR Therapies for the Treatment of Metastatic Colorectal Cancer
Fakih, M., & Vincent, M. (2010) · Current Oncology · doi:10.3747/co.v17is1.615 · Cited by 109
Prevalence of type I sensitization to alpha‐gal in forest service employees and hunters
Fischer, J., Lupberger, E., Hebsaker, J., Blumenstock, G., Aichinger, E., Yazdi, A. S., Reick, D., Oehme, R., & Biedermann, T. (2017) · Allergy · doi:10.1111/all.13156 · Cited by 147
Immunogenicity assessment of biotherapeutic products: An overview of assays and their utility
Wadhwa, M., Knezevic, I., Kang, H.-N., & Thorpe, R. (2015) · Biologicals · doi:10.1016/j.biologicals.2015.06.004 · Cited by 145
Antibody recognition of carbohydrate epitopes
Haji‐Ghassemi, O., Blackler, R. J., Young, N. M., & Evans, S. V. (2015) · Glycobiology · doi:10.1093/glycob/cwv037 · Cited by 168
Xie, H., Chakraborty, A., Ahn, J., Yu, Y. Q., Dakshinamoorthy, D. P., Gilar, M., Chen, W., Skilton, S. J., & Mazzeo, J. R. (2010) · mAbs · doi:10.4161/mabs.11986 · Cited by 145
del Val, I. J., Kontoravdi, C., & Nagy, J. M. (2010) · Biotechnology Progress · doi:10.1002/btpr.470 · Cited by 139
Tick-induced allergies: mammalian meat allergy, tick anaphylaxis and their significance
van Nunen, S. (2015) · Asia Pacific Allergy · doi:10.5415/apallergy.2015.5.1.3 · Cited by 143
Allergens and their role in the allergic immune response
Platts‐Mills, T. A. E., & Woodfolk, J. A. (2011) · Immunological Reviews · doi:10.1111/j.1600-065x.2011.01021.x · Cited by 142
Self-citationDiaz, S. L., Padler-Karavani, V., Ghaderi, D., Hurtado-Ziola, N., Yu, H., Chen, X., Brinkman-Van der Linden, E. C. M., Varki, A., & Varki, N. M. (2009) · PLoS ONE · doi:10.1371/journal.pone.0004241 · Cited by 146
Erwin, E. A., James, H. R., Gutekunst, H. M., Russo, J., Kelleher, K. J., & Platts‐Mills, T. A. E. (2010) · Annals of Allergy Asthma & Immunology · doi:10.1016/j.anai.2010.03.018 · Cited by 160
Self-citationTaking immunogenicity assessment of therapeutic proteins to the next level
Büttel, I., Chamberlain, P., Chowers, Y., Ehmann, F., Greinacher, A., Jefferis, R., Kramer, D., Kropshofer, H., Lloyd, P. M., Lubiniecki, A. S., et al. (2011) · Biologicals · doi:10.1016/j.biologicals.2011.01.006 · Cited by 153
Self-citationTherapeutic monoclonal antibody N-glycosylation – Structure, function and therapeutic potential
Cymer, F., Beck, H., Rohde, A., & Reusch, D. (2017) · Biologicals · doi:10.1016/j.biologicals.2017.11.001 · Cited by 160
Controversies in drug allergy: In vitro testing
Mayorga, C., Ebo, D. G., Lang, D. M., Pichler, W. J., Sabato, V., Park, M. A., Makowska, J. S., Atanasković‐Marković, M., Bonadonna, P., & Jares, E. J. (2018) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2018.09.022 · Cited by 148
Gonzalez‐Quintela, A., Dam Laursen, A. S., Vidal, C., Skaaby, T., Gude, F., & Linneberg, A. (2014) · Clinical & Experimental Allergy · doi:10.1111/cea.12326 · Cited by 139
Rispens, T., Derksen, N. I. L., Commins, S. P., Platts-Mills, T. A., & Aalberse, R. C. (2013) · PLoS ONE · doi:10.1371/journal.pone.0055566 · Cited by 136
Self-citationHaemaphysalis longicornis tick bites are a possible cause of red meat allergy in Japan
Chinuki, Y., Ishiwata, K., Yamaji, K., Takahashi, H., & Morita, E. (2016) · Allergy · doi:10.1111/all.12804 · Cited by 132
Environmental and Molecular Drivers of the α-Gal Syndrome
Cabezas-Cruz, A., Hodžić, A., Román-Carrasco, P., Mateos-Hernández, L., Duscher, G. G., Sinha, D. K., Hemmer, W., Swoboda, I., Estrada-Peña, A., & de la Fuente, J. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01210 · Cited by 131
Glycoengineering of Antibodies for Modulating Functions
Wang, L., Tong, X., Li, C., Giddens, J. P., & Li, T. (2019) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-062917-012911 · Cited by 148
Immunotoxicity of monoclonal antibodies
Descotes, J. (2009) · mAbs · doi:10.4161/mabs.1.2.7909 · Cited by 140
Cohen, R. B. (2013) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2013.10.002 · Cited by 147
Current Knowledge and Management of Hypersensitivity Reactions to Monoclonal Antibodies
Picard, M., & Galvão, V. R. (2017) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2016.12.001 · Cited by 146
Commins, S. P., & Platts-Mills, T. A. E. (2013) · Current Allergy and Asthma Reports · doi:10.1007/s11882-012-0315-y · Cited by 134
Self-citationTick bites and red meat allergy
Commins, S. P., & Platts‐Mills, T. A. E. (2013) · Current Opinion in Allergy and Clinical Immunology · doi:10.1097/aci.0b013e3283624560 · Cited by 147
Self-citationWarrington, R., Silviu-Dan, F., & Wong, T. (2018) · Allergy Asthma and Clinical Immunology · doi:10.1186/s13223-018-0289-y · Cited by 157
Galactose-α-1,3-galactose and Delayed Anaphylaxis, Angioedema, and Urticaria in Children
Kennedy, J. L., Stallings, A. P., Platts-Mills, T. A. E., Oliveira, W. M., Workman, L., James, H. R., Tripathi, A., Lane, C. J., Matos, L., Heymann, P. W., et al. (2013) · Pediatrics · doi:10.1542/peds.2012-2585 · Cited by 132
Self-citationAcute infusion reactions induced by monoclonal antibody therapy
Maggi, E., Vultaggio, A., & Matucci, A. (2010) · Expert Review of Clinical Immunology · doi:10.1586/eci.10.90 · Cited by 137
Mabelane, T., Basera, W., Botha, M., Thomas, H. F., Ramjith, J., & Levin, M. E. (2018) · Pediatric Allergy and Immunology · doi:10.1111/pai.12969 · Cited by 128
IgE Antibodies: From Structure to Function and Clinical Translation
Sutton, B. J., Davies, A. M., Bax, H. J., & Karagiannis, S. N. (2019) · Antibodies · doi:10.3390/antib8010019 · Cited by 152
Platts-Mills, T. A. E., Commins, S. P., Biedermann, T., van Hage, M., Levin, M., Beck, L. A., Diuk-Wasser, M., Jappe, U., Apostolovic, D., Minnicozzi, M., et al. (2020) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2020.01.047 · Cited by 129
Self-citationMechanisms of Drug-Induced Allergy
Schnyder, B., & Pichler, W. J. (2009) · Mayo Clinic Proceedings · doi:10.4065/84.3.268 · Cited by 151
An Update of Efficacy and Safety of Cetuximab in Metastatic Colorectal Cancer: A Narrative Review
Fornasier, G., Francescon, S., & Baldo, P. (2018) · Advances in Therapy · doi:10.1007/s12325-018-0791-0 · Cited by 134
Cutaneous reactions to chemotherapeutic drugs and targeted therapy for cancer
Reyes-Habito, C. M., & Roh, E. K. (2014) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2014.04.013 · Cited by 146
Picard, M., Özyiğit, L. P., Caiado, J., Junior, P. F. G.-B., Galvão, V. R., Berlin, S. T., Campos, S. M., Matulonis, U. A., & Castells, M. (2015) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2015.10.039 · Cited by 141
Macro- and Micro-Heterogeneity of Natural and Recombinant IgG Antibodies
Beck, A., & Liu, H. (2019) · Antibodies · doi:10.3390/antib8010018 · Cited by 138
Clinical Relevance of Cross-Reactivity in Food Allergy
Cox, A. L., Eigenmann, P. A., & Sicherer, S. H. (2021) · The Journal of Allergy and Clinical Immunology: In Practice · doi:10.1016/j.jaip.2020.09.030 · Cited by 128
Immunogenicity assessment during the development of protein therapeutics
Rosenberg, A. S., & Sauna, Z. E. (2018) · Journal of Pharmacy and Pharmacology · doi:10.1111/jphp.12810 · Cited by 131
Clinical development methodology for infusion‐related reactions with monoclonal antibodies
Doessegger, L., & Banholzer, M. L. (2015) · Clinical & Translational Immunology · doi:10.1038/cti.2015.14 · Cited by 127
Epidermal growth factor receptor targeted therapy of squamous cell carcinoma of the head and neck
Sharafinski, M. E., Ferris, R. L., Ferrone, S., & Grandis, J. R. (2010) · Head & Neck · doi:10.1002/hed.21365 · Cited by 138
Cutting‐edge mass spectrometry characterization of originator, biosimilar and biobetter antibodies
Beck, A., Debaene, F., Diemer, H., Wagner‐Rousset, E., Colas, O., Dorsselaer, A. V., & Cianférani, S. (2015) · Journal of Mass Spectrometry · doi:10.1002/jms.3554 · Cited by 123
Virus-like particle display of HER2 induces potent anti-cancer responses
Palladini, A., Thrane, S., Janitzek, C. M., Pihl, J., Clemmensen, S. B., de Jongh, W. A., Clausen, T. M., Nicoletti, G., Landuzzi, L., Penichet, M. L., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2017.1408749 · Cited by 140
Design of glycosylation sites by rapid synthesis and analysis of glycosyltransferases
Kightlinger, W., Liang, L., Rosztoczy, M., Li, W., DeLisa, M. P., Mrksich, M., & Jewett, M. C. (2018) · Nature Chemical Biology · doi:10.1038/s41589-018-0051-2 · Cited by 134
Targeted therapies in squamous cell carcinoma of the head and neck
Gold, K. A., Lee, H., & Kim, E. S. (2009) · Cancer · doi:10.1002/cncr.24123 · Cited by 129
Chung, A. W., Crispin, M., Pritchard, L., Robinson, H., Gorny, M. K., Yu, X., Bailey-Kellogg, C., Ackerman, M. E., Scanlan, C., Zolla-Pazner, S., et al. (2014) · AIDS · doi:10.1097/qad.0000000000000444 · Cited by 122
van Bueren, J. J. L., Rispens, T., Verploegen, S. A. B. W., van der Palen‐Merkus, T., Stapel, S. O., Workman, L. J., James, H. R., van Berkel, P. H. C., van de Winkel, J. G. J., Platts‐Mills, T. A. E., et al. (2011) · Nature Biotechnology · doi:10.1038/nbt.1912 · Cited by 136
Self-citationJacquenet, S., Moneret‐Vautrin, D. A., & Bihain, B. E. (2009) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2009.06.014 · Cited by 126
Cianferoni, A. (2021) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2021.02.012 · Cited by 116
Serum albumins—Unusual allergens
Chruszcz, M., Mikolajczak, K., Mank, N., Majorek, K. A., Porebski, P. J., & Minor, W. (2013) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2013.06.016 · Cited by 119
Role of siglecs and related glycan-binding proteins in immune responses and immunoregulation
Bochner, B. S., & Zimmermann, N. (2015) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2014.11.031 · Cited by 113
The future of antibodies as cancer drugs
Reichert, J. M., & Dhimolea, E. (2012) · Drug Discovery Today · doi:10.1016/j.drudis.2012.04.006 · Cited by 136
Oettgen, H. C. (2016) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2016.04.009 · Cited by 114
Bhattacharyya, S., Liu, H., Zhang, Z., Jam, M., Dudeja, P. K., Michel, G., Linhardt, R. J., & Tobacman, J. K. (2010) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2009.07.002 · Cited by 120
Gunn, G. R., Sealey, D., Jamali, F., Meibohm, B., Ghosh, S. K., & Shankar, G. (2015) · Clinical & Experimental Immunology · doi:10.1111/cei.12742 · Cited by 123
Hypersensitivity to Biological Agents—Updated Diagnosis, Management, and Treatment
Galvão, V. R., & Castells, M. (2015) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2014.12.006 · Cited by 122
Immunogenicity risk assessment and mitigation for engineered antibody and protein therapeutics
Carter, P. J., & Quarmby, V. E. (2024) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-01051-x · Cited by 133
N-Glycosylation of Plant-produced Recombinant Proteins
Bosch, D., Castilho, A., Loos, A., Schots, A., & Steinkellner, H. (2013) · Current Pharmaceutical Design · doi:10.2174/1381612811319310006 · Cited by 121
Monoclonal Antibodies: Past, Present and Future
Posner, J., Barrington, P. J., Brier, T., & Datta‐Mannan, A. (2019) · Handbook of experimental pharmacology · doi:10.1007/164_2019_323 · Cited by 130
Kannicht, C., Ramström, M., Kohla, G., Tiemeyer, M., Casademunt, E., Walter, O., & Sandberg, H. (2013) · Thrombosis Research · doi:10.1016/j.thromres.2012.09.011 · Cited by 120
van Schie, K. A., Wolbink, G.-J., & Rispens, T. (2015) · mAbs · doi:10.1080/19420862.2015.1048411 · Cited by 117
Emergence and significance of carbohydrate-specific antibodies
Kappler, K., & Hennet, T. (2020) · Genes & Immunity · doi:10.1038/s41435-020-0105-9 · Cited by 118
Dissecting cross-reactivity in hymenoptera venom allergy by circumvention of α-1,3-core fucosylation
Seismann, H., Blank, S., Braren, I., Greunke, K., Cifuentes, L., Grunwald, T., Bredehorst, R., Ollert, M. W., & Spillner, E. (2009) · Molecular Immunology · doi:10.1016/j.molimm.2009.10.005 · Cited by 118
Adverse reactions to biologic agents and their medical management
Boyman, O., Comte, D., & Spertini, F. (2014) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2014.123 · Cited by 127
Clinical Efficacy and Toxicity of Anti-EGFR Therapy in Common Cancers
Harandi, A., Zaidi, A. S., Stocker, A. M., & Laber, D. A. (2009) · Journal of Oncology · doi:10.1155/2009/567486 · Cited by 116
Delayed anaphylaxis to alpha-gal, an oligosaccharide in mammalian meat
Commins, S. P., Jerath, M. R., Cox, K. M., Erickson, L. D., & Platts‐Mills, T. A. E. (2015) · Allergology International · doi:10.1016/j.alit.2015.10.001 · Cited by 120
Self-citationWilson, J. M., & Platts-Mills, T. A. E. (2018) · Molecular Immunology · doi:10.1016/j.molimm.2018.03.018 · Cited by 105
Self-citationExploring the N-glycosylation Pathway in Chlamydomonas reinhardtii Unravels Novel Complex Structures
Mathieu-Rivet, E., Scholz, M., Arias, C., Dardelle, F., Schulze, S., Le Mauff, F., Teo, G., Hochmal, A. K., Blanco-Rivero, A., Loutelier-Bourhis, C., et al. (2013) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m113.028191 · Cited by 109
Jajosky, R. P., Wu, S.-C., Zheng, L., Jajosky, A. N., Jajosky, P. G., Josephson, C. D., Hollenhorst, M. A., Sackstein, R., Cummings, R. D., Arthur, C. M., et al. (2023) · iScience · doi:10.1016/j.isci.2022.105798 · Cited by 110
IgE in the diagnosis and treatment of allergic disease
Platts-Mills, T. A. E., Schuyler, A. J., Erwin, E. A., Commins, S. P., & Woodfolk, J. A. (2016) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2016.04.010 · Cited by 104
Self-citationWilson, J. M., Nguyen, A. T., Schuyler, A. J., Commins, S. P., Taylor, A. M., Platts-Mills, T. A. E., & McNamara, C. A. (2018) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.118.311222 · Cited by 108
Self-citationImmunogenicity and other problems associated with the use of biopharmaceuticals
Tovey, M. G., & Lallemand, C. (2011) · Therapeutic Advances in Drug Safety · doi:10.1177/2042098611406318 · Cited by 108
Tick exposures and alpha-gal syndrome: A systematic review of the evidence
Young, I., Prematunge, C., Pussegoda, K., Corrin, T., & Waddell, L. (2021) · Ticks and Tick-borne Diseases · doi:10.1016/j.ttbdis.2021.101674 · Cited by 94
Sjögren, J., Olsson, F., & Beck, A. (2016) · The Analyst · doi:10.1039/c6an00071a · Cited by 104
He, S., Zhang, H., Zeng, X., Chen, D., & Yang, P. (2013) · Acta Pharmacologica Sinica · doi:10.1038/aps.2013.88 · Cited by 113
Hock, M. B., Thudium, K. E., Carrasco‐Triguero, M., & Schwabe, N. F. (2014) · The AAPS Journal · doi:10.1208/s12248-014-9684-6 · Cited by 117
Biosimilar, biobetter and next generation therapeutic antibodies
Beck, A. (2011) · mAbs · doi:10.4161/mabs.3.2.14785 · Cited by 104
Biosimilarity and Interchangeability: Principles and Evidence: A Systematic Review
McKinnon, R. A., Cook, M., Liauw, W., Marabani, M., Marschner, I. C., Packer, N. H., & Prins, J. B. (2018) · BioDrugs · doi:10.1007/s40259-017-0256-z · Cited by 114
Glyco‐engineering in plants to produce human‐like N‐glycan structures
Castilho, A., & Steinkellner, H. (2012) · Biotechnology Journal · doi:10.1002/biot.201200032 · Cited by 105
Role of ErbB family receptor tyrosine kinases in intrahepatic cholangiocarcinoma
Sirica, A. E. (2008) · World Journal of Gastroenterology · doi:10.3748/wjg.14.7033 · Cited by 108
Torres, M. J., Romano, A. G., Celik, G., Demoly, P. M., Khan, D. A., Macy, E. M., Park, M., Blumenthal, K. G., Aberer, W., Castells, M., et al. (2017) · Clinical and Translational Allergy · doi:10.1186/s13601-017-0144-0 · Cited by 107
Kaur, H. (2021) · Critical Reviews in Biotechnology · doi:10.1080/07388551.2020.1869684 · Cited by 109
Analytical comparability study of recombinant monoclonal antibody therapeutics
Ambrogelly, A., Gozo, S., Katiyar, A., Dellatore, S. M., Kune, Y., Bhat, R., Sun, J., Li, N., Wang, D., Nowak, C., et al. (2018) · mAbs · doi:10.1080/19420862.2018.1438797 · Cited by 106
Site-selective chemoenzymatic glycoengineering of Fab and Fc glycans of a therapeutic antibody
Giddens, J. P., Lomino, J. V., DiLillo, D. J., Ravetch, J. V., & Wang, L. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1812833115 · Cited by 108
The role of cetuximab for the treatment of squamous cell carcinoma of the head and neck.
Mehra, R., Cohen, R. B., & Burtness, B. A. (2008) · PubMed · Cited by 102
Mathieu‐Rivet, E., Kiefer‐Meyer, M., Vanier, G., Ovide, C., Burel, C., Lerouge, P., & Bardor, M. (2014) · Frontiers in Plant Science · doi:10.3389/fpls.2014.00359 · Cited by 114
D’Atri, V., Fekete, S., Beck, A., Lauber, M., & Guillarme, D. (2017) · Analytical Chemistry · doi:10.1021/acs.analchem.6b04726 · Cited by 96
Caballero, M. L., Krantz, M. S., Quirce, S., Phillips, E. J., & Stone, C. A. (2021) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2021.03.002 · Cited by 105
Hypersensitivity reactions to biologicals: An EAACI position paper
Bavbek, S., Pagani, M., Álvarez-Cuesta, E., Castells, M., Dursun, A. B., Hamadi, S. A., Madrigal‐Burgaleta, R., Sanchez‐Sanchez, S., & Vultaggio, A. (2021) · Allergy · doi:10.1111/all.14984 · Cited by 111
Coping with cross-reactive carbohydrate determinants in allergy diagnosis
Altmann, F. (2016) · Allergo Journal International · doi:10.1007/s40629-016-0115-3 · Cited by 99
Kurogochi, M., Mori, M., Osumi, K., Tojino, M., Sugawara, S.-I., Takashima, S., Hirose, Y., Tsukimura, W., Mizuno, M., Amano, J., et al. (2015) · PLOS ONE · doi:10.1371/journal.pone.0132848 · Cited by 96
Glycosylation control technologies for recombinant therapeutic proteins
Gupta, S. K., & Shukla, P. (2018) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-018-9430-6 · Cited by 107
Fischer, J., Yazdi, A. S., & Biedermann, T. (2016) · Allergo Journal International · doi:10.1007/s40629-016-0099-z · Cited by 93
Anaphylaxis epidemic: Fact or fiction?
Simons, F. E. R., & Sampson, H. A. (2008) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2008.10.019 · Cited by 98
Fc gamma receptors: glycobiology and therapeutic prospects
Hayes, J. M., Wormald, M. R., Rudd, P. M., & Davey, G. P. (2016) · Journal of Inflammation Research · doi:10.2147/jir.s121233 · Cited by 103
Hilger, C., Fischer, J., Wölbing, F., & Biedermann, T. (2019) · Current Allergy and Asthma Reports · doi:10.1007/s11882-019-0835-9 · Cited by 92
SweetBac: A New Approach for the Production of Mammalianised Glycoproteins in Insect Cells
Palmberger, D., Wilson, I. B. H., Berger, I., Grabherr, R. M., & Rendić, D. (2012) · PLoS ONE · doi:10.1371/journal.pone.0034226 · Cited by 108
Pratt, K. P. (2018) · Antibodies · doi:10.3390/antib7020019 · Cited by 96
Metadata
- Authors
- Chung, C. H., Mirakhur, B., Chan, E., Le, Q.-T., Berlin, J., Morse, M., Murphy, B. A., Satinover, S. M., Hosen, J., Mauro, D., Slebos, R. J., Zhou, Q., Gold, D., Hatley, T., Hicklin, D. J., & Platts-Mills, T. A. E.
- Affiliations
- Vanderbilt University (US)
- Bristol-Myers Squibb (United States) (US)
- Stanford University (US)
- Duke Medical Center (US)
- University of Virginia (US)
- Harvard University (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2008-03-13
- Volume
- 358
- Issue
- 11
- Pages
- 1109-1117
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC2361129
- OpenAlex
- W2140035322
- Cited by
- 1,521
- References
- 35
- Citations by year
- 2026: 63 · 2025: 79 · 2024: 64 · 2023: 83 · 2022: 78 · 2021: 78 · 2020: 94 · 2019: 80 · 2018: 78 · 2017: 109 · 2016: 90 · 2015: 99 · 2014: 88 · 2013: 97 · 2012: 94
- FWCI
- 57.43
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Damon Runyon Cancer Research Foundation
- Bristol-Myers Squibb
- Vanderbilt University
- Robert J. Kleberg, Jr. and Helen C. Kleberg Foundation
- National Institutes of Health (20565, 2r01ai020565-29, 5r01ca118582-05, AI-20565)
- U.S. Public Health Service (AI-AADCRC-U19-070364)
- National Cancer Institute (R01-CA-118582, P50CA095103, P50CA95103)
- National Institute of Allergy and Infectious Diseases (AI 20565, R01AI035796, R01AI-020565, AI/EHS-35796, R29AI035796, R37AI020565)
- National Institute of Dental and Craniofacial Research (R01DE017982)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Drug-Induced Adverse Reactions
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Health Sciences › Medicine › Immunology and Allergy › Food Allergy and Anaphylaxis Research
- Keywords
- cetuximab, anaphylaxis, drug hypersensitivity, IgE antibodies, galactose-alpha-1,3-galactose, Fab fragment, monoclonal antibodies, epidermal growth factor receptor, pre-existing antibodies, colorectal cancer, head and neck squamous cell carcinoma
- MeSH terms
- Cetuximab, Adult, Aged, Aged, 80 and over, Anaphylaxis, Antibodies, Monoclonal, Epitopes, Antineoplastic Agents, Cross Reactions, Disaccharides, Female, Humans, Immunoglobulin E, Male, Middle Aged, Protein Binding, Protein Conformation, Case-Control Studies, Antibodies, Monoclonal, Humanized, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.